Q-omics provides the consensus-scored MIR618 profile across patient tissues and cancer cell-line models. MIR618 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR618 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR618 RNA expression shows 8,142 significant gene co-expression associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, and BRCA as cancer lineages where MIR618 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR618 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR618 survival associations across molecular data types. MIR618 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR618 RNA expression–survival associations across cancer types. High MIR618 expression shows unfavorable associations in BLCA, BRCA, KICH, STAD, KIRC and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .017). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR618 RNA expression.
This table summarizes MIR618 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR618. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR618 shows higher tumor expression in BRCA and KICH. The BRCA box plot shows higher MIR618 RNA expression in tumor versus normal tissue (log2 FC = +0.122, t-test p = .004).
This table shows molecular features associated with MIR618 in patient tissues and cancer cell lines. In patient samples, MIR618 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
